Allworth Financial LP Has $1.85 Million Stock Holdings in Novo Nordisk A/S $NVO

Allworth Financial LP trimmed its position in shares of Novo Nordisk A/S (NYSE:NVO) by 44.9% in the 2nd quarter, Holdings Channel.com reports. The fund owned 38,586 shares of the company’s stock after selling 31,404 shares during the quarter. Allworth Financial LP’s holdings in Novo Nordisk A/S were worth $1,850,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Godfrey Financial Associates Inc. acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $25,000. Scarborough Advisors LLC bought a new position in Novo Nordisk A/S during the first quarter valued at approximately $26,000. Transamerica Financial Advisors LLC lifted its stake in Novo Nordisk A/S by 201.5% in the fourth quarter. Transamerica Financial Advisors LLC now owns 603 shares of the company’s stock valued at $31,000 after acquiring an additional 403 shares during the last quarter. Continuum Advisory LLC acquired a new stake in Novo Nordisk A/S in the second quarter valued at approximately $38,000. Finally, Johnson Financial Group Inc. grew its position in Novo Nordisk A/S by 128.0% in the third quarter. Johnson Financial Group Inc. now owns 684 shares of the company’s stock worth $38,000 after acquiring an additional 384 shares in the last quarter. Institutional investors and hedge funds own 11.54% of the company’s stock.

Novo Nordisk A/S Trading Down 2.2%

Shares of NVO stock opened at $43.03 on Friday. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $64.16. The company has a market cap of $192.15 billion, a PE ratio of 10.52, a price-to-earnings-growth ratio of 1.48 and a beta of 0.74. The company has a quick ratio of 0.56, a current ratio of 0.79 and a debt-to-equity ratio of 0.59. The business’s 50 day moving average is $47.49 and its two-hundred day moving average is $43.65.

Novo Nordisk A/S (NYSE:NVO) last issued its quarterly earnings data on Tuesday, June 30th. The company reported $0.94 earnings per share for the quarter. The business had revenue of $11.98 billion during the quarter. Novo Nordisk A/S had a net margin of 35.36% and a return on equity of 61.20%. Equities analysts predict that Novo Nordisk A/S will post 3.45 EPS for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently announced a dividend, which was paid on Tuesday, August 25th. Shareholders of record on Monday, August 17th were given a dividend of $0.5786 per share. The ex-dividend date of this dividend was Monday, August 17th. This represents a yield of 258.0%. Novo Nordisk A/S’s payout ratio is currently 19.80%.

More Novo Nordisk A/S News

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy received approval in China for MASH, making it the first GLP-1 receptor agonist in the country approved for the liver disease. The decision expands semaglutide’s potential beyond obesity and diabetes, although Novo has not provided a launch schedule or revenue outlook. Reuters article
• Positive Sentiment: China’s acceptance of Novo’s oral Wegovy application creates a potential avenue into the country’s growing GLP-1 weight-management market. Investors see the opportunity as a possible long-term growth driver, though regulatory approval, launch timing and competitive dynamics remain uncertain. Oral Wegovy China article
• Neutral Sentiment: HSBC raised its price target to 320 Danish kroner but kept a Hold rating, reflecting improved valuation expectations without a strong near-term conviction. HSBC price target article
• Positive Sentiment: Some analysts continue to view Novo’s valuation, strong margins, free cash flow and GLP-1 leadership as providing a margin of safety, suggesting the recent weakness may already reflect substantial execution and competitive risks. Novo Nordisk valuation analysis
• Negative Sentiment: The Morgan Stanley downgrade is the dominant near-term catalyst. Investors are questioning whether oral Wegovy, China expansion and other pipeline opportunities can replace revenue exposed to the semaglutide patent cliff, contributing to NVO’s decline and keeping sentiment weak. Morgan Stanley downgrade article

Analyst Upgrades and Downgrades

Several brokerages have recently commented on NVO. Zacks Research upgraded shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, August 11th. BMO Capital Markets reiterated a “market perform” rating and issued a $47.00 price objective on shares of Novo Nordisk A/S in a report on Thursday, August 6th. Deutsche Bank Aktiengesellschaft downgraded shares of Novo Nordisk A/S from a “hold” rating to a “sell” rating in a research report on Thursday, August 27th. Wall Street Zen lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Saturday, June 20th. Finally, Nordea Equity Research raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Friday, June 19th. Four equities research analysts have rated the stock with a Buy rating, fourteen have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $64.94.

About Novo Nordisk A/S

Novo Nordisk A/S is a Danish healthcare company headquartered in Bagsværd, Denmark. Founded in 1923, the company develops and manufactures pharmaceutical products focused primarily on diabetes and obesity care, as well as treatments for rare blood disorders and growth disorders.

Its diabetes portfolio includes insulin products and medicines in the glucagon-like peptide-1 (GLP-1) class, including Ozempic, Rybelsus and Wegovy. The company also offers treatments for obesity, hemophilia and other rare conditions, along with growth hormone therapies.